GlassScriptPhysician profile
Regina N Mills
NPI 1831725001
$3,974.02
in general payments reported to CMS, 2019-2025
44 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $333 · 2023: $816 · 2024: $344 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,178.70 |
| Education | $280.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $411.07 | 2023-2025 | Erleada, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $407.14 | 2022-2025 | Enhertu, Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $316.91 | 2022-2025 | |
| Pfizer INC. | $299.51 | 2023-2025 | |
| Astellas Pharma US INC | $240.81 | 2022-2025 | Vyloy |
| Seagen INC. | $214.27 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.22 | 2023-2025 | Opdivo, Reblozyl, Eliquis |
| Inari Medical, INC. | $181.24 | 2021 | |
| Kite Pharma, INC. | $121.81 | 2023 | |
| Karyopharm Therapeutics INC. | $119.80 | 2023 | Xpovio |
| Incyte Corporation | $109.30 | 2025 | Monjuvi, Jakafi |
| Pharmacosmos Therapeutics INC. | $108.07 | 2024-2025 | Monoferric |
| Array Biopharma INC | $106.01 | 2025 | Braftovi, Mektovi, Xalkori |
| Takeda Pharmaceuticals U.S.A., INC. | $93.41 | 2022-2025 | Iclusig, Fruzaqla, Ninlaro |
| Daiichi Sankyo INC. | $92.31 | 2025 | Enhertu, Datroway |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.